Oculis Holding AGNASDAQ:OCS
- LAST PRICE12.0200
- TODAY'S CHANGE (%)0.0700 (0.5858%)
- Bid / Lots11.5300/ 1
- Ask / Lots12.5000/ 4
- Open / Previous Close12.0100 / 11.9500
- Day Range
- 52 Week Range
- Volume88,399
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OCS |
|---|---|---|
| 09:32 ET | 34686 | 12.01 |
| 09:34 ET | 2732 | 12.01 |
| 09:36 ET | 5514 | 12.01 |
| 09:39 ET | 2008 | 12.01 |
| 09:41 ET | 1300 | 12.01 |
| 10:01 ET | 550 | 12.01 |
| 10:03 ET | 2550 | 12.04 |
| 10:08 ET | 100 | 12.03 |
| 10:12 ET | 340 | 12.025 |
| 10:19 ET | 100 | 12.03 |
| 10:21 ET | 100 | 12.03 |
| 10:24 ET | 430 | 12.03 |
| 10:26 ET | 438 | 12.03 |
| 10:28 ET | 770 | 12.0399 |
| 10:30 ET | 1061 | 12.03 |
| 11:06 ET | 100 | 12.01 |
| 11:08 ET | 100 | 12.01 |
| 11:09 ET | 200 | 12.0172 |
| 11:11 ET | 100 | 12.01 |
| 11:27 ET | 100 | 12.01 |
| 11:36 ET | 125 | 12.0104 |
| 11:42 ET | 100 | 12.01 |
| 11:45 ET | 200 | 12.01 |
| 11:49 ET | 200 | 12.01 |
| 11:51 ET | 100 | 12.015 |
| 12:02 ET | 300 | 12.01 |
| 12:05 ET | 100 | 12.01 |
| 12:12 ET | 200 | 12.01 |
| 12:14 ET | 235 | 12.01 |
| 12:38 ET | 847 | 12.01 |
| 12:43 ET | 100 | 12.01 |
| 12:45 ET | 100 | 12.01 |
| 01:19 ET | 106 | 12.01 |
| 01:32 ET | 100 | 12.01 |
| 01:53 ET | 2000 | 12.0101 |
| 01:57 ET | 7149 | 12.01 |
| 02:02 ET | 2607 | 12.01 |
| 02:13 ET | 6115 | 12.01 |
| 03:00 ET | 100 | 12.01 |
| 03:05 ET | 100 | 12.01 |
| 03:16 ET | 100 | 12.01 |
| 03:18 ET | 100 | 12.01 |
| 03:23 ET | 100 | 12.01 |
| 03:41 ET | 110 | 12.01 |
| 03:50 ET | 100 | 12.01 |
| 03:56 ET | 100 | 12.01 |
| 03:59 ET | 900 | 12.02 |
Apr 24, 2024
DJ Oculis Holding Is Maintained at Buy by HC Wainwright & Co., from 6:37AM ET on Wednesday Apr 24, 2024 by Dow Jones
6:37AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 22, 2024
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market, from 9:27AM ET on Monday Apr 22, 2024 by Dow Jones
9:27AM ET on Monday Apr 22, 2024 by Dow Jones
Apr 11, 2024
Apr 10, 2024
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development, from 6:30AM ET on Wednesday Apr 10, 2024 by Dow Jones
6:30AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 8, 2024
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting, from 6:30AM ET on Monday Apr 08, 2024 by Dow Jones
6:30AM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oculis Holding AG | 499.3M | 0.0x | --- |
GH Research PLC | 546.3M | -15.4x | --- |
Mineralys Therapeutics Inc | 547.9M | -6.6x | --- |
Korro Bio Inc | 542.7M | -0.9x | --- |
Olema Pharmaceuticals Inc | 549.6M | -4.6x | --- |
Compass Pathways PLC | 537.2M | -3.3x | --- |
Company Information
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Contact Information
- Headquarters
- Bahnhofstrasse 7ZUG, ZUG, Switzerland 6300
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Anthony Rosenberg
- Chief Executive Officer, Director
- Riad Sherif
- Chief Financial Officer
- Sylvia Cheung
- Head - Medical Affairs
- Joanne Chang
- Head - Development
- Bastian Dehmel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $499.3M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 41.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $2.80 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
